Arcadia Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $(4,385) | $2,599 |
| Adjustments to reconcile net income to cash used in operating activities: | ||
| Change in fair value of common stock warrant and option liabilities | (1,191) | (1,862) |
| Change in fair value of contingent consideration | — | (1,000) |
| Issuance and offering costs | 421 | — |
| Loss on January 2026 Inducement Offer | 2,877 | — |
| Depreciation | 8 | 13 |
| Lease amortization | — | 104 |
| Amortization of note receivable | — | (69) |
| Gain on sale of intangible assets | — | (750) |
| Unrealized loss subsequent to receipt of Above Food Ingredients, Inc. common stock | 1,538 | — |
| Stock-based compensation | 15 | 78 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | — | (193) |
| Inventories | 372 | (381) |
| Prepaid expenses and other current assets | (28) | 205 |
| Accounts payable and accrued expenses | (719) | (213) |
| Other current liabilities | (7) | — |
| Operating lease liabilities | — | (119) |
| Net cash used in operating activities | (1,099) | (1,588) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of intangible assets | — | 500 |
| Net cash provided by investing activities | — | 500 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from January 2026 Inducement Offer | 2,082 | — |
| Payments of offering costs relating to January 2026 Inducement Offer | (288) | — |
| Proceeds from ESPP purchases | — | 5 |
| Net cash provided by financing activities | 1,794 | 5 |
| Net increase (decrease) in cash and cash equivalents | 695 | (1,083) |
| Cash and cash equivalents — beginning of period | 259 | 4,242 |
| Cash and cash equivalents — end of period | $954 | $3,159 |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Proceeds from sale of intangible assets in accounts receivable and other receivables | $— | $250 |
| Accrued legal fees included in offering costs related to January 2026 Inducement Offer | $62 | $— |
| Preferred investment options issued to placement agent and included in offering costs related to January 2026 Inducement Offer | $71 | |
| Warrant and option modifications included in Loss on January 2026 Inducement Offer | $555 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.